The Regulator, is fully aware of the very sketchy track history of this scam biotech company, and there is no way that they will ever be allowed to fleece both the NHS &/ or its most vulnerable patients. Like wise, the NICE will be simply unable to cost this 'treatment', especially given how its 'success' rate was derived at, using 'pic n mix' data.
Market Data 
Markets 
AI
